Han and colleagues reported that atractylenolide III (5, 10 mg/kg) could ameliorate DSS-induced colitis inflammatory and oxidative stress by regulating the MDA and GSH contents, SOD activity, and the expression of TNF-α, IL-6, COX-2, and iNOS mRNA. The gene discussed is TNF; the disease is colitis.